Despite preclinical studiesdemonstrating the anti-inflammatory potential of PAD4 inhibitors and MK blockers,the clinical translation of these compounds remains hindered by obstacles, suchas the high heterogeneity of myocarditis and recruitment difficulties for trialsof rare diseases. This evidence concerns the gene MDK and myocarditis.